cross-linking (cxl) surgery.
Conditions
Interventions
Intervention 1: Intervention group: One hour before surgery, they receive a single dose of 75 mg slow-release indomethacin tablets made in Iran and Aria Pharmaceutical Company. Intervention 2: Control
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 35 Years
Inclusion criteria
Inclusion criteria: Male and female patients between 16 and 35 years of age included unlikely consecutive sampling of significant keratoconus with readings greater than 47 d and central corneal thickness greater than 400um.
Exclusion criteria
Exclusion criteria: patients with a history of eye surgery, acute corneal hydrops, dense corneal ectasia, corneal opacity, any history of NSAID allergies, or the use of topical / systemic anti-inflammatory drugs are excluded from the study within two weeks prior to surgery. Also, patients with a BMI of less than 18.5 and more than 30 are excluded from the study due to changes in the use of analgesic doses for pharmacological effects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Pain Scale (VAS) Score. Timepoint: Visual Pain Scale (VAS) questionnaire is determined at 4 hours after surgery and the number of analgesics used during 24 hours after surgery. Method of measurement: Visual Pain Scale (VAS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaezeh Mazidi Sharafabadi
Yazd University of Medical Sciences
Outcome results
None listed